Aptorum Group Aktie 

2,62EUR
+0,04EUR
+1,55%
24.06.2021
3,18USD
+0,01USD
+0,32%
00:28:13
Hier für 0 Euro handeln mit
mehr Daten anzeigen
Werbung

Aptorum Group Aktien News

26.05.21Aptorum Group CEO Subscribed Shares In The Company (Businesswire)
24.05.21Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma (Businesswire)
13.05.21Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference (Businesswire)
06.05.21Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions (Businesswire)
23.04.21Aptorum Group Limited Interview to Air on Bloomberg Television U.S. on the RedChip Money Report (Businesswire)
22.04.21Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases (Businesswire)
19.04.21Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update (Businesswire)
16.10.20Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020 (Businesswire)
02.10.20Aptorum Group Announces Closing of $9.0 Million Public Offering (Businesswire)
30.09.20Aptorum Group Announces Pricing of $9.0 Million Public Offering (Businesswire)
08.09.20Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10 (Businesswire)
08.09.20Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance (Businesswire)
02.09.20Aptorum Group Announces Video Update Discussing Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types (Businesswire)
01.09.20Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models (Businesswire)
01.09.20Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types (Businesswire)
01.09.20Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020 (Businesswire)
28.08.20Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report (Businesswire)
26.08.20Aptorum Group Limited to Present at The LD 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Life Sciences Conference (Businesswire)
20.08.20Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others (Businesswire)
24.07.20Aptorum Group wird das erste an der Nasdaq notierte biopharmazeutische Unternehmen, dessen Aktien zum Handel an der Pariser Börse Euronext zugelassen werden (Ticker-Symbol APM) (Businesswire)
24.07.20Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM (Businesswire)
17.07.20Prospekt der Aptorum Group erhält Genehmigung für Notierung an der Börse Euronext Paris (Businesswire)
17.07.20Aptorum Group Prospectus Receives Approval for Listing on the Euronext Paris Stock Exchange (Businesswire)
15.06.20Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman (Businesswire)
29.05.20Aptorum Group Interview to Air on Bloomberg International on the RedChip Money Report (Businesswire)
18.05.20Aptorum Group to Hold Investor Webinar and Q&A Session with President on May 19 (Businesswire)
29.04.20Aptorum Group Limited Reports 2019 Fiscal Year End Financial Results and Provides Business Update (Businesswire)
29.04.20Aptorum Group Limited to Present at the Infectious Disease Virtual Conference (Businesswire)
30.03.20Aptorum Group Limited to Present at the Solebury Trout Virtual Investor Conference (Businesswire)
30.03.20Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress (Businesswire)
28.02.20Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants (Businesswire)
26.02.20Aptorum Group Announces Pricing of $10 Million Registered Direct Offering (Businesswire)
24.02.20Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong (Businesswire)
24.02.20Aptorum Group beginnt Vermarktung von bioaktiven nutrazeutischen Tabletten mit Dioscorea Opposita und unterzeichnet Vertriebsvereinbarung in Hongkong (Businesswire)
10.02.20Aptorum Group meldet bedeutende Fortschritte des umgewidmeten Wirkstoffkandidaten SACT-1 bei Neuroblastom und strebt Einreichung eines IND-Antrags im zweiten Halbjahr 2020 an (Businesswire)
10.02.20Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020 (Businesswire)
15.11.19Aptorum Group Limited Announces Results of 2019 Annual General Meeting (Businesswire)
09.09.19Aptorum Group gibt die Entwicklung eines Wirkstoffkandidaten aus dem Mikrobiom zur Behandlung von Adipositas und umgewidmeter Wirkstoffkandidaten zur Behandlung von Neuroblastomen bekannt (Businesswire)
09.09.19Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma (Businesswire)
09.09.19Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019 (Businesswire)
Seite: 12

Aptorum Group News

Aptorum Group News: auf dieser Seite finden Sie alle Aptorum Group News und Nachrichten zur Aptorum Group Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Aptorum Group News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Aptorum Group News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung

Meistgelesene Aptorum Group News

Keine Nachrichten gefunden.
Weitere Aptorum Group News

Aptorum Group Peer Group News

Keine Nachrichten gefunden.
finanzen.net Brokerage
finanzen.net Zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln